BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, February 27, 2026
Home » Blogs » BioWorld MedTech Perspectives » Chickens or lemmings? Washington and the FDA budget

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology / FDA

Chickens or lemmings? Washington and the FDA budget

Sep. 16, 2012
By Mark McCarty

There’s a lot of consternation and maybe even a little constipation of late about the U.S. federal budget, and rightly so. If the White House and Congress can’t come to some resolution about budget sequestration, the FDA budget could tighten enough that user fees would disappear, which would cripple the agency. Complicating matters further is the series of tax issues – a convergence dubbed the fiscal cliff – that ripen at the end of this year, giving everyone inside the Beltway more to worry about.

This is all difficult enough without an election, so it’s easy to be pessimistic. And it’s tough to tell whether this is a game of chicken between Republicans and Democrats, or a case of lemmings of all stripes headed over a cliff.

So, how worried should we be?

As matters stand, the House of Representatives has passed a continuing resolution to fund government operations for the first six months of fiscal 2013 at roughly current levels. So far, so good, especially since the user fee calendar aligns with the federal fiscal year. All that waits now is a Senate vote, which President Obama can be safely presumed to sign.

The situation at FDA is a really outstanding reason to give the cooler heads in Washington more time at the mike. After all, there’s nothing like the specter of counterfeit drugs and devices flooding American medicine cabinets and hospitals to give a legislator a queasy stomach. There isn’t a whole lot of clarity on the question of whether sequestration would affect device user fees, as Mark Leahey, President/CEO of the Medical Device Manufacturers Association told me last week. And a lot of people would argue FDA is about as useful as a screen door in a submarine should the sequester damage or eliminate all the various user fees at FDA.

As for the tax issues that make up the fiscal cliff, I suspect the outcome will help the economy at least a little no matter which way it goes. Assuming business is still on the sidelines over unpredictability, even a tax increase would bolster some additional investment if only because everyone would then know what they’re working with. Incidentally, whoever is sitting in the Oval Office after inauguration day will get some credit for an economic boost, regardless of whether they helped (or hindered) the process.

So I think our elected officials will muddle through the budget and the fiscal cliff. Easy to say, I know, but believe it or not, all those cynical you-know-whats in Washington really do care. Besides, who wants to go down in history as the clown posse who ran the world’s largest economy into the ground?

Beyond that, anyone who needs votes to keep their job has to remember that this big a deal won’t be forgotten if they botch it, and in that event it won’t be a case of lemmings running over the cliff come election day 2014. It’ll be a case of chickens being heaved over the cliff by an angry mob. If nothing else gets Washington’s attention, that will.

Popular Stories

  • Today's news in brief

    BioWorld
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld
    Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
  • 3D rendering of skin cells and elastin with collagen layer

    First-in-class pan-inflammasome blocker for hidradenitis suppurativa

    BioWorld Science
    Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
  • Illustration of cancer cell in crosshairs being destroyed

    RX-10616 improves radiotherapy efficacy in HNSCC

    BioWorld Science
    Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
  • Brain and virus with chromosome

    CROI 2026: Neurodegeneration, the challenge of aging with HIV

    BioWorld
    Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing